Johnson and Johnson: The subcutaneous formulation of Rybrevant was more effective than the intravenous formulation in reducing the risk of death in lung cancer patients.
- The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination with Lazertinib.
- The subcutaneous version had a shorter infusion time and showed better tolerability than the intravenous version, with lower rates of infusion-related adverse reactions.
The Latest
In the PALOMA study, a phase 3 randomized trial composed of 418 patients with advanced or metastatic non-small cell lung cancer, the injectable version of Rybrevant used in combination with Lazertinib significantly reduced the risk of death compared to intravenous Rybrevant with Lazertinib. In addition, the subcutaneous version had a shorter infusion time and showed better tolerability than the intravenous version, with lower rates of infusion-related reactions.
Physician’s Perspective
Lung cancer is the leading cause of cancer-related mortality in the US and worldwide. Approximately 80% of lung cancers are classified as non-small cell lung cancer (NSCLC). There are targeted therapies available for NSCLC tumors expressing targeted driver mutations in proteins such as epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK), c-ROS oncogene 1 (ROS1), and BRAF. However, current therapies for NSCLC with EGFR mutations have a reduced efficacy against a subset of these cancers with slight mutation differences. Rybrevant circumvents these differences, allowing therapies to be effective.
Molecular Target of Therapy
In patients with NSCLC, mutations in the protein gene encoding epidermal growth factor receptor (EGFR) are common. One of the most common types of EGFR mutations is insertions in exon 20 of EGFR, which limit the binding of tyrosine kinase inhibitors and the use of currently available targeted therapies. Rybrevant is an EGFR and mesenchymal-epithelial transition factor (MET) bispecific antibody that can recruit immune effector cells to tumor cells expressing EGFR with exon 20 insertions, thereby leading to the destruction of tumor cells.
Company History
Johnson and Johnson is an American pharmaceutical company founded in 1886. In addition to the PALOMA study, Rybrevant is being studied in multiple other clinical trials in patients with NSCLC. In addition to Rybrevant, Johnson and Johnson has multiple other targeted therapies in development for patients with refractory multiple myeloma and chronic lymphocyte leukemia.
©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
